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High mobility group protein B1 (HMGB1) is a late inflammatory mediator that exaggerates septic symptoms. Adiponectin,
an adipokine, has potent anti-inflammatory properties. However, possible effects of adiponectin on lipopolysaccharide- (LPS-)
inducedHMGB1 release are unknown.The aimof this studywas to investigate effects of full length adiponectin onHMGB1 release in
LPS-stimulated RAW 264 macrophage cells. Treatment of the cells with LPS alone significantly induced HMGB1 release associated
with HMGB1 translocation from the nucleus to the cytosol. However, prior treatment with adiponectin suppressed LPS-induced
HMGB1 release and translocation.The anti-inflammatory cytokine interleukin- (IL-) 10 similarly suppressed LPS-inducedHMGB1
release. Adiponectin treatment decreased toll-like receptor 4 (TLR4) mRNA expression and increased heme oxygenase- (HO-) 1
mRNA expression without inducing IL-10 mRNA, while IL-10 treatment decreased TLR2 and HMGB1 mRNA expression and
increased the expression of IL-10 andHO-1mRNA. Treatment with the HO-1 inhibitor ZnPP completely prevented the suppression
of HMGB1 release by adiponectin but only partially inhibited that induced by IL-10. Treatment with compound C, an AMP kinase
(AMPK) inhibitor, abolished the increase in HO-1 expression and the suppression of HMGB1 release mediated by adiponectin.
In conclusion, our results indicate that adiponectin suppresses HMGB1 release by LPS through an AMPK-mediated and HO-1-
dependent IL-10-independent pathway.
1. Introduction
Sepsis, an almost universally fatal clinical syndrome that is
caused bymicrobial infection, results from excess stimulation
of the host immune system by pathogen components to pro-
duce various proinflammatory cytokines [1]. Overproduction
of these cytokines causes systemic inflammation that can lead
to tissue damage, multiple organ failure, and death [2, 3]. For
example, bacterial lipopolysaccharides (LPS), a cell wall com-
ponent of gram-negative bacteria, induces an acute inflam-
matory response initiated by its interaction with toll-like
receptor 4 (TLR4) resulting in sequential release of “early”
(e.g., tumor necrosis factor- (TNF-) 𝛼, interleukin- (IL-) 1,
and IL-6) and “late” (e.g., high mobility group protein B1
(HMGB1)) proinflammatory cytokines [4–6]. However, ther-
apies designed to block early released cytokines such as TNF-
𝛼 or IL-1𝛽 have shown limited efficacy due to the early and
transient kinetics of the production of these inflammatory
cytokines [7, 8].
HMGB1 is a highly conserved, ubiquitous nonhistone
nuclear protein that exhibits diverse functions according
to its cellular location. Nuclear HMGB1 participates in
DNA replication, recombination, transcription, and repair. In
response to infection or injury, HMGB1 is actively secreted by
innate immune cells and/or passively released by injured or
damaged cells. Once released,HMGB1 bindswith cell-surface
receptors, such as the receptor for advanced glycation end
products (RAGE) and/or TLRs including TLR2 and TLR4
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and mediates various cellular responses, infiltration of innate
immune cells, and subsequent release of various proinflam-
matory cytokines [9–12]. Administration of recombinant
HMGB1 to mice is lethal, while administration of anti-
HMGB1 antibodies or inhibitors provides protection against
LPS-induced acute tissue damage and lethal endotoxaemia
[4, 11, 13, 14]. Therefore, targeting HMGB1 release provides
a wide window for clinical intervention against systemic
inflammatory diseases.
Adiponectin, which is also known as adipocyte comple-
ment-related protein (Acrp30), is one of the most abundant
ones of the bioactive molecules called adipokines that are
secreted from adipose tissue [15]. Adiponectin plays an
important role in various physiological processes including
lipid metabolism, insulin sensitization, and anti-inflamma-
tory responses [16–18]. Evidence indicates that adiponectin
suppresses the “early” phase of macrophage inflammatory
responses. For example, adiponectin reduces macrophage
differentiation and migration [19] and promotes macrophage
polarization toward an anti-inflammatoryM2phenotype both
in vivo and in cultured macrophages [20, 21]. Adiponectin
also inhibits the upregulation of the expression of adhesion
molecules and the enhancement of phagocytic activity and
cytokine production in LPS-stimulated macrophages [19,
22], whereas it increases the release of anti-inflammatory
mediators such as IL-10 and IL-1 receptor antagonist from
macrophages [23].
A number of animal studies show that adiponectin has
a protective effect against the development of inflammation
related disorders. For example, treatment with adiponectin
improves atherosclerosis through inhibition of macrophage
aggregation [19] and improves nonalcoholic steatohepatitis
via inhibition of lipogenic factors and TNF-𝛼 [24]. Moreover,
adiponectin protects from endotoxin-induced disorders of
organs including the liver [25], the lung [26], and the heart
[27], although its deficiency is associated with severe polymi-
crobial sepsis with high mortality [28]. However, there has
been no published report regarding the effects of adiponectin
on the regulation of endotoxin-mediated release of “late”
proinflammatory mediators such as HMGB1. Therefore, in
this study, we investigated the effect of adiponectin on LPS-
induced HMGB1 release in murine RAW 264 macrophage
cells.
2. Materials and Methods
2.1. Materials. Rabbit anti-HMGB1 antibody was purchased
from Cell Signaling Technology (CST) (Beverly, MA, USA).
Recombinant mouse full length adiponectin expressed in
HEK293 cells was purchased from Biovendor (Asheville,
NC, USA). Recombinant murine IL-10 was purchased from
PeproTech (Rocky Hill, NJ, USA). Zinc protoporphyrin IX
(ZnPP) was purchased from Frontier Scientific (Logan, UT,
USA). SB203580, compound C (dorsomorphin), wortman-
nin, and bovine serum albumin (BSA) were purchased from
Sigma-Aldrich Fine Chemicals (St. Louis, MO, USA). OPTI-
MEM Iwas purchased from Invitrogen (Carlsbad, CA, USA).
2.2. Cell Culture. Cells of the murine macrophage-like cell
line RAW 264 (RCB0535, RIKEN Cell Bank, Japan) were
maintained in Dulbecco’s modified Eagle’s medium (DMEM,
Wako Pure Chemicals, Osaka, Japan) and supplemented with
10% fetal bovine serum (FBS, Trace Scientific Ltd.,Melbourne,
Australia), 100U/mL penicillin, and 100 𝜇g/mL streptomycin
in an atmosphere of humidified 5% CO
2
at 37∘C. When the
cells reached 80–90% confluence, they were washed twice
with, and subsequently cultured in, serum-free OPTI-MEM
I for 12 h before all treatments. The cells were treated with
or without increasing concentrations of adiponectin or IL-
10 for 18 h and were then stimulated with LPS (Escherichia
coli O55:B5, Sigma-Aldrich) dissolved in phosphate buffer
saline (PBS) at a concentration of 200 ng/mL for another
24 h. When included, the cells were treated with or without
ZnPP, SB203580, compound C, or wortmannin 1 h before
adiponectin (10𝜇g/mL) or IL-10 (100 ng/mL) addition.
2.3.Western BlottingAnalysis. The level ofHMGB1 in the cul-
ture medium was determined by western blotting analysis as
previously reported [29–32]. Briefly, culturemedium samples
were centrifuged to remove cellular debris, then concentrated
60-fold with the Amicon Ultra-4-10000 NMWL (Millipore,
Billerica, MA, USA). The concentrated samples were mixed
with SDS loading buffer (500mM Tris-HCl, 10% SDS, 0.5%
bromophenol blue, and 5% 2-mercaptoethanol), boiled at
100∘C for 5min, separated on 15% SDS-polyacrylamide gels,
and transferred onto a polyvinylidene fluoride membrane
(Immobilon, Millipore). The membrane was incubated in a
blocking buffer (20mM Tris-HCl (pH 7.5), 150mM NaCl,
0.1% Tween 20 (TBS-T), and 5% skimmed milk) and then
with rabbit anti-HMGB1 polyclonal antibody (1 : 2000 dilu-
tion in the blocking buffer) overnight at 4∘C. Subsequently,
the membrane was washed with TBS-T for 15min and
incubated with horseradish peroxidase-linked goat anti-
rabbit immunoglobulin (CST) (1 : 5000 dilution in the block-
ing buffer) for 1 h at room temperature. The signals were
visualized using chemiluminescent HRP Substrate (Milli-
pore) according to the manufacturer’s instructions and were
detected using the ImageQuant LAS 500 system (GE Health-
care, Buckinghamshire, UK).The intensity of chemilumines-
cence of the corresponding bands was quantified using Image
J software (v. 1.48, http://imagej.nih.gov/ij/).
2.4. Quantitative Real-Time PCR (qRT-PCR). Total RNA was
extracted from RAW 264 cells using the RNAiso reagent
(Takara Bio, Shiga, Japan) according to the manufacturer’s
protocol. Total RNA (2𝜇g) was reverse transcribed using a 15-
mer oligo (dT) adaptor primer andM-MLVreverse transcrip-
tase (Invitrogen). Quantitative real-time PCR was performed
on a fluorescence thermal cycler (Light Cycler system, Roche
Diagnostics, Mannheim, Germany) using FastStart Essential
DNA Green Master PCR kits (Roche Diagnostics). Expres-
sion levels were determined using the standard curvemethod
with respective cDNA fragments as standards. The levels are
reported relative to Gapdh expression as an internal control.
The primer sequences used in this study and the length of
each PCR product are listed in Table 1.
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Table 1: Primer sequences for quantitative real-time PCR and the length of each PCR product.
Mouse gene Gene product Foreword primer Reverse primer Product size (bp)
Gapdh GAPDH GAAGGTCGGTGTGAACGGATT GAAGACACCAGTAGACTCCAC 294
Hmgb1 HMGB1 GGGAGACCAAAAAGAAGTTC GGCAGCTTTCTTCTCATAGG 200
Hmox1 HO-1 TTCAGAAGGGTCAGGTGTCC CAGTGAGGCCCATACCAGAA 193
Il-10 IL-10 GCCAAGCCTTATCGGAAATG TTTTCACAGGGGAGAAATCG 163
Ly96 MD2 ACGCTGCTTTCTCCCATATT CATTGGTTCCCCTCAGTCTT 150
Nfe2l2 Nrf2 ACATGGAGCAAGTTTGGCAG TGGAGAGGATGCTGCTGAAA 235
Sirtuin1 SIRT1 AGGGAACCTTTGCCTCATCT GAGGTGTTGGTGGCAACTCT 159
Sirtuin6 SIRT6 ACCTGCAACCCACAAAACAT GGCTCAGCCTTGAGTGCTAC 178
Tlr2 TLR2 CGGAGGTAGAGTTCGACGAC AACTGGGGGATATGCAACCT 127
Tlr4 TLR4 CAGCAAAGTCCCTGATGACA AGAGGTGGTGTAAGCCATGC 179
2.5. Immunofluorescence. Thecellular localization ofHMGB1
was investigated using an immunofluorescence staining
assay. RAW264 cells (5× 104 cells/well) were cultured on glass
coverslips in 6-well plates. The cells were washed twice with
PBS and then fixed with 4% paraformaldehyde for 30min
at room temperature. Subsequently, the cells were permeabi-
lized with 10% Triton X-100 in PBS supplemented with 0.5%
BSA and 0.15% glycine for 10min, following which they were
blocked in PBS containing 5% BSA and 0.3% Triton X-100 for
60min. The glass coverslips were then incubated with rabbit
anti-HMGB1 antibody (1 : 100 dilution in PBS containing 1%
BSA and 0.3% Triton X-100) overnight at 4∘C, followed by
goat anti-rabbit Alexa flour 488 (1 : 400 dilution) (Invitrogen)
in the dark for 1 h at room temperature. Cells were washed
with PBS containing 0.1% Triton X-100 between all incuba-
tions steps, followed by a final wash in PBS. Nuclei were
labeled by incubation with 4󸀠,6-diamidino-2-phenylindole
(DAPI, Invitrogen) for 10min. The cells were washed three
times for 5min with PBS. The coverslips were mounted on
slides using ProlongAntifade Reagents (Invitrogen). Images
were captured using a fluorescence microscope (Biorevo
BZ-9000, Keyence Japan, Osaka, Japan) with a ×100 oil-
immersion lens. No fluorescence was detected in control cells
processed without the primary antibody. The fluorescence
intensities of cytosolic and nuclear HMGB1 were quantified
using Image J software.
2.6. Statistical Analysis. IBMSPSS Statistics version 22.0 soft-
ware (SPSS, Chicago, IL, USA) was used for statistical analy-
sis. Data are presented as means ± standard error (SE). Statis-
tical comparisons between multiple groups were performed
with one-way analysis of variance (ANOVA) followed by
either Dunnett’s or a Tukey HSD post hoc test. A 𝑝 value of <
0.05 was considered statistically significant.
3. Results
RAW 264 cells released a small amount of HMGB1 into the
medium under the culture conditions without any stimula-
tion. The amount of HMGB1 that was released increased 6-
fold upon stimulation of the cells with 200 ng/mL of LPS
(Figure 1(a)). Cell viability was almost 100% even after treat-
ment with 1 𝜇g/mL of LPS (data not shown). The increased
release of HMGB1 with LPS treatment was accompanied
by HMGB1 translocation from the nucleus to the cytosol
(Figures 1(b) and 1(c)). These results suggested that HMGB1
release was under the control of LPS signaling rather than
being passive release due to LPS cytotoxicity. Prior treatment
of the cells with full length adiponectin failed to affect
basal HMGB1 release but dose dependently suppressed LPS-
induced HMGB1 release and was accompanied by nuclear
localization of most of the HMGB1 (Figures 1(a)–1(c)).
As it has been reported that globular adiponectin exerts
its anti-inflammatory actions through induction of IL-10 [21],
we next examined the effect of IL-10 on LPS induction of
HMGB1 release. Prior treatment of the cells with IL-10 also
failed to enhance basal HMGB1 release. However, IL-10 at
doses of 50 and 100 ng/mL greatly decreased the HMGB1
release into the medium that was induced by LPS (Figure 2).
To further examine the mechanism behind the suppres-
sive effect of adiponectin on LPS-induced HMGB1 release,
we compared mRNA expression in cells treated with either
full length adiponectin or IL-10. Among the genes quantified,
RAW 264 cells constitutively expressed TLR4 mRNA, TLR2
mRNA, and myeloid differentiation factor 2 (MD2) mRNA
(Figures 3(a)–3(c)), all of which are plasma membrane
components responsible for LPS binding and signaling.
Treatment of the cells with adiponectin selectively decreased
expression of TLR4 mRNA, while IL-10 treatment reduced
only TLR2 mRNA expression. Distinct differences between
full length adiponectin and IL-10 treatments were also
observed in the expression of HMGB1 and IL-10 genes. The
cells constitutively expressedHMGB1mRNA,whichwas sup-
pressed only by IL-10 treatment and not by adiponectin treat-
ment (Figure 3(d)). On the other hand, the cells expressed
very low levels of IL-10 mRNA, which was enhanced only by
IL-10 treatment, but not by full length adiponectin treatment
(Figure 3(e)).Thus, it was unlikely that full length adiponectin
exerted its suppressive effect on LPS-inducedHMGB1 release
through induction of IL-10.
Interestingly, both IL-10 and full length adiponectin
treatments enhanced the mRNA expression of HO-1, a
downstream anti-inflammatory effector of IL-10 signaling

















































































Figure 1: Effect of recombinant adiponectin on LPS-induced HMGB1 release and HMGB1 cellular translocation. Raw 264 cells were cultured
in DMEM supplemented with 10% FBS and were cultured in serum-free OPTI-MEM Imedium for additional 12 h.The cells were treated with
increasing concentrations of adiponectin for 18 h, then stimulated with LPS (200 ng/mL) for another 24 h. (a) Culture medium was collected
and analyzed by HMGB1 western blotting, followed by quantification of the intensity of the chemiluminescent HMGB1 band. The results are
expressed as means ± SE of three independent experiments (∗∗𝑝 < 0.01 significance compared with control; #𝑝 < 0.05 significance compared
with LPS treated cells). (b and c) Cellular HMGB1 was immunostained with an anti-HMGB1 rabbit primary and Alexa Fluor 488 anti-rabbit
secondary antibodies. The nucleus was stained with DAPI. Merge indicates the combination of both HMGB1 (Green) and nuclear (Blue)
fluorescence. The fluorescence intensities of cytosolic and nuclear HMGB1 in (b) were separately analyzed and the ratio of cytosolic HMGB1
to nuclear HMGB1 is shown in (c) (∗∗𝑝 < 0.01 significance compared with control; ##𝑝 < 0.01 significance compared with LPS treated cells).
(Figure 3(f)), while neither treatment affected the mRNA
expression of nuclear factor erythroid-derived 2 related factor
2 (Nrf2), a transcription factor relatedwithHO-1 gene expres-
sion (Figure 3(g)). In addition, neither IL-10 nor full length
adiponectin treatment increased the mRNA expression of
Sirt1 or Sirt6, which are histone deacetylases that function as
a chromatin silencer to regulate recombination and genomic
stability (Figures 3(h) and 3(i)). We therefore next examined
the involvement of HO-1 in the suppressive effect of full
length adiponectin on LPS-induced HMGB1 release. Treat-
ment of the cells with zinc protoporphyrin (ZnPP), a HO-
1 inhibitor, did not have any effect on HMGB1 release from
either LPS-stimulated or control cells (Figure 4). However,
treatment with ZnPP for 1 h before full length adiponectin
treatment almost completely abolished adiponectin sup-
pression of LPS-induced HMGB1 release, although it only





































Figure 2: Effect of recombinant IL-10 on LPS-induced HMGB1 release. Raw 264 cells were cultured as described in Figure 1 legend and were
treated with IL-10 for 18 h, then stimulated with LPS (200 ng/mL) for another 24 h. Culture medium was collected and analyzed by HMGB1
western blotting followed by quantification of the intensity of the chemiluminescent HMGB1 band. The results are expressed as means ± SE
of three independent experiments (∗∗𝑝 < 0.01 significance compared with control; ##𝑝 < 0.01 and #𝑝 < 0.05 significance compared with LPS
treated cells).
slightly inhibited the suppression by IL-10. These results
indicate that increased expression of HO-1 in response to
full length adiponectin is necessary for adiponectin-mediated
prevention of LPS-induced HMGB1 release.
We then examined whether increased expression of HO-
1 mRNA by full length adiponectin was mediated through
AMP-activated kinase (AMPK), a main signaling pathway
of adiponectin action [33–35]. Treatment of the cells with
compound C, an AMPK inhibitor, abolished the increase in
expression ofHO-1mRNAby full length adiponectin, whereas
treatment of the cells with wortmannin, a phosphatidylinosi-
tol-3-kinase (PI3K) inhibitor, or with SB203580, a p38
mitogen-activated protein kinase (p38MAPK) inhibitor, did
not affect this increase (Figure 5). Consistent with these
results, treatment of the cells with compound C, but not
with SB203580, abolished adiponectin-mediated suppression
of LPS-induced HMGB1 release (Figure 6).
4. Discussion
In the present study, we demonstrated for the first time
that full length adiponectin prevents LPS-induced HMGB1
translocation from the nucleus to the cytosol and its subse-
quent release from Raw 264 mouse macrophage cells. This
process is most probably mediated by AMPK-dependent
HO-1 induction, as evidenced by the following results. Both
AMPK and HO-1 inhibitors prevented the suppression of
LPS-induced HMGB1 release by full length adiponectin
and the AMPK inhibitor also prevented induction of HO-1
mRNA by full length adiponectin. Furthermore, the mech-
anism of the full length adiponectin effect is supported by
previous reports that showed that full length adiponectin
activates AMPK activity [33–35], that activation of AMPK
by metformin or dehydrodiconiferyl alcohol enhances HO-
1 expression and its activity [36, 37], and that HO-1 is
indispensable for the prevention of HMGB1 release [38,
39]. Of course, other events such as selective reduction in
TLR4 mRNA expression by full length adiponectin might
contribute, at least in part, to the suppression of LPS-
induced HMGB1 release, since TLR4 is the predominant
receptor for LPS [40, 41] and a similar decrease in cell-surface
TLR4 expression is seen in macrophage cells treated with
globular adiponectin [42]. However, other intracellular sig-
naling pathways related to p38MAPK, PI3K, and the nuclear
histone deacetylase sirtuin are unlikely to be involved in the
mechanism, although they have been reported to be involved
in some adiponectin functions [43–46] or in the processes of
HO-1 induction and LPS-induced HMGB1 release [47–49].
We have also demonstrated that IL-10 is a potent inhibitor
of LPS-induced HMGB1 release. However, the fact that full
length adiponectin failed to induce IL-10 mRNA suggested
that the suppression by full length adiponectin might not be
attributed to IL-10 production. This hypothesis is supported
by previous findings that the effects of full length adiponectin
on macrophage function are independent of IL-10 [42, 44],
although anti-inflammatory effects of globular adiponectin
are mediated by IL-10 [21, 23, 50–52]. The discrepancy
between the role of IL-10 in the effects of full length and
globular adiponectin has not been explored but is possibly
due to different signals mediated through adipoR2 and
adipoR1, respectively [42].
Accumulating evidence indicates that HO-1 plays a piv-
otal role in the anti-inflammatory cytoprotective effects of a
wide variety of compounds including statins, phytochemicals
such as resveratrol, and aspirin [53]. HO-1 is a microsomal
enzyme that catalyzes the degradation of proinflammatory
free heme and produces equimolar amounts of carbon
monoxide, bilirubin, and iron [54]. The mechanisms that
mediate the anti-inflammatory effects of HO-1 are not fully
understood, but the potent antioxidant activity of bilirubin
and the signaling gas activity of carbon monoxide are
reported to suppress apoptosis, necrosis, inflammation, and
oxidative stress. Interestingly, HO-1 is induced by pathophys-
iological stimuli including LPS and hemodynamic changes,











































































































































































Figure 3: Effects of adiponectin and IL-10 on mRNA expression in RAW 264 cells. Raw 264 cells were cultured as described in Figure 1
legend and were treated with adiponectin (APN, 10𝜇g/mL) and IL-10 (100 ng/mL) for 18 h. RNA was extracted, and expressions of (a) TLR4,
(b) TLR2, (c)MD2, (d) HMGB1, (e) IL-10, (f) HO-1, (g) Nrf2, (h) Sirt1, (i) Sirt6, and Gapdh (control) mRNAs weremeasured using qRT-PCR.
The results are expressed as means ± SE of three independent experiments (∗∗∗𝑝 < 0.001 and ∗𝑝 < 0.05 significance compared with control
(Cont)).
but in most cases pathophysiological activation of HO-1
results in only a transient or marginal increase in HO-1
that falls below the threshold necessary to activate down-
stream components such as carbon monoxide [53]. In the
present study, a fourfold increase in HO-1 mRNA expression
compared to its basal expression was induced by full length
adiponectin, whereas only a twofold increase was induced
by IL-10. Combined with the result that the HO-1 inhibitor
only partially abrogated the suppression by IL-10 of LPS-
induced HMGB1 release, these findings suggested that IL-10































































Figure 4: Effect of an HO-1 inhibitor on the anti-inflammatory
action of adiponectin or IL-10 on LPS-induced HMGB1 release.
Raw 264 cells were cultured as described in Figure 1 legend and
were treated with dimethyl sulfoxide (DMSO, control) or ZnPP
(1 𝜇M) for 1 h before treatment with adiponectin (10𝜇g/mL) or
IL-10 (100 ng/mL) for 18 h. Cells were then stimulated with LPS
(200 ng/mL) for another 24 h. Culture medium was collected and
analyzed by HMGB1 western blotting followed by quantification of
the intensity of the chemiluminescent HMGB1 band.The results are
expressed as means ± SE of three independent experiments (∗∗𝑝 <
0.01 significance compared with control; ##𝑝 < 0.01 and #𝑝 < 0.05
significance compared with LPS treated cells; +𝑝 < 0.05 significance
compared with LPS plus ZnPP treated cells).
SB203580 WortmanninCompound C



















Figure 5: Effect of kinase inhibitors on adiponectin-induced HO-1
mRNA expression in RAW 264 cells. Raw 264 cells were cultured
as described in Figure 1 legend and were treated with adiponectin
(10𝜇g/mL) for 18 h in the presence of DMSO (control), compound
C (10 𝜇M), wortmannin (1 𝜇M), or SB203580 (10𝜇M). RNA was
extracted, and expressions of Hmox1 (HO-1) and Gapdh mRNAs
weremeasured using qRT-PCR.The results are expressed asmeans±
SE of three independent experiments (∗∗∗𝑝 < 0.001 and ∗∗𝑝 < 0.01
significance compared with control).
induces only a marginal increase in HO-1 mRNA and mainly
utilizes an HO-1-independent pathway for the suppression of
HMGB1 release.
In summary, we provide the novel finding that full length
adiponectin suppresses HMGB1 release by LPS through
an AMPK-HO-1-dependent pathway. Therefore, adiponectin




















































































Figure 6: Effect of kinase inhibitors on the suppression by
adiponectin of LPS-induced HMGB1 release. Raw 264 cells were
cultured as described in Figure 1 legend and were treated with
compound C (a) or SB203580 (b) for 1 h before treatment with
adiponectin (10𝜇g/mL) for 18 h, following which they were stimu-
lated with LPS (200 ng/mL) for another 24 h. Culture media were
collected and analyzed by HMGB1 western blotting followed by
quantification of the intensity of the chemiluminescent HMGB1
band. The results are expressed as means ± SE of three independent
experiments (∗∗∗𝑝 < 0.001 and ∗∗𝑝 < 0.01 significance compared
with control; #𝑝 < 0.05 significance comparedwith LPS treated cells;
+
𝑝 < 0.05 significance compared with LPS plus SB203580 treated
cells).
through inhibition of both early and late proinflammatory
mediators under pathological conditions such as sepsis.
Thus, it is possible that adiponectin might be a target for
development of therapeutic agents against sepsis and other
systemic inflammatory disorders.
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